Ironwood Pharmaceuticals (IRWD) Set to Announce Earnings on Tuesday
Ironwood Pharmaceuticals (NASDAQ:IRWD) is scheduled to release its Q313 earnings data on Tuesday, October 22nd. Analysts expect Ironwood Pharmaceuticals to post earnings of ($0.57) per share and revenue of $6.54 million for the quarter.
Ironwood Pharmaceuticals (NASDAQ:IRWD) last issued its quarterly earnings data on Tuesday, July 23rd. The company reported ($0.57) EPS for the quarter, beating the Thomson Reuters consensus estimate of ($0.70) by $0.13. The company had revenue of $9.70 million for the quarter, compared to the consensus estimate of $6.32 million. During the same quarter in the prior year, the company posted ($0.38) earnings per share. The company’s quarterly revenue was down 33.6% on a year-over-year basis. On average, analysts expect Ironwood Pharmaceuticals to post $-2.53 EPS for the current fiscal year and $-1.55 EPS for the next fiscal year.
Shares of Ironwood Pharmaceuticals (NASDAQ:IRWD) traded down 3.27% during mid-day trading on Monday, hitting $10.35. 1,393,064 shares of the company’s stock traded hands. Ironwood Pharmaceuticals has a 52-week low of $9.83 and a 52-week high of $19.67. The stock’s 50-day moving average is $11.97 and its 200-day moving average is $12.86. The company’s market cap is $1.174 billion.
Several analysts have recently commented on the stock. Analysts at Zacks reiterated an “outperform” rating on shares of Ironwood Pharmaceuticals in a research note to investors on Wednesday, October 16th. They now have a $13.00 price target on the stock. On the ratings front, analysts at UBS AG cut their price target on shares of Ironwood Pharmaceuticals from $10.50 to $9.00 in a research note to investors on Tuesday, October 15th. They now have a “sell” rating on the stock. Two investment analysts have rated the stock with a sell rating, nine have assigned a hold rating and six have given a buy rating to the stock. The company currently has an average rating of “Hold” and an average price target of $13.95.
Ironwood Pharmaceuticals, Inc is a pharmaceutical company, which discovers, develops and intends to commercialize differentiated medicines.
Get Analysts' Upgrades and Downgrades via Email - Stay on top of analysts' coverage with Analyst Ratings Network's FREE daily email newsletter that provides a concise list of analysts' upgrades and downgrades. Click here to register now.